From AI-powered drug discovery to regenerative therapies and next-generation neurology tools, Mayo Clinic researchers made ...
LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic ...
In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform ...
LoQus23 Therapeutics, based at Granta Park in Cambridge, has stepped up its bid to combat Huntington’s Disease (HD). It has ...
Researchers at the University of St Andrews have uncovered a long‑elusive molecular 'reshuffle', a breakthrough that tackles ...
Research efforts are ongoing to develop safer, broad-spectrum antivenoms. Technology Networks sat down with Dr. Andreas ...
This study in neonatal rats revealed that the common inhaled pediatric anesthetic, sevoflurane, impairs neurogenesis and ...
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced CiFi, a new community-developed method that enables chromosome-scale, haplotype-resolved genome ...
Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by ...
While late M-stars are the easiest places to find Earth-sized planets, a new study suggests they are biological dead ends where animal life may never find enough fuel to evolve.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback